Mineralys appoints Karydas and Sblendorio to board after Takahashi resignation

Mineralys Therapeutics, Inc.

Takeshi Takahashi resigned from board on Sept 12; no disagreement cited.
Board expanded to 8 members; appointed Daphne Karydas (Class III) and Glenn Sblendorio (Class II) effective Sept 13.
Karydas named audit committee chair; Sblendorio named compensation committee chair.
Each new director received options to purchase 44,000 shares vesting monthly over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Takeshi Takahashi

Director

MLYS · Mineralys Therapeutics, Inc.

Effective: 2023-09-12
Filed: September 14, 2023, 7:59 PM ET

On September 12, 2023, Takeshi Takahashi, M.B.A., resigned from the Board of Directors (the "Board") of Mineralys Therapeutics, Inc. (the "Company").

Appointed

Glenn P. Sblendorio

Director

MLYS · Mineralys Therapeutics, Inc.

Effective: 2023-09-13
Filed: September 14, 2023, 7:59 PM ET

the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board.

Appointed

Daphne Karydas

Director

MLYS · Mineralys Therapeutics, Inc.

Effective: 2023-09-13
Filed: September 14, 2023, 7:59 PM ET

the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Takeshi Takahashi resigned as Director at Mineralys Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 12, 2023, Takeshi Takahashi, M.B.A., resigned from the Board of Directors (the "Board") of Mineralys Therapeutics, Inc. (the "Company").

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Glenn P. Sblendorio was appointed as Director at Mineralys Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daphne Karydas was appointed as Director at Mineralys Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board.

View on SEC.gov

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-23-000076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.